

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 February 2024 (15.02.2024)



(10) International Publication Number
WO 2024/031181 A1

(51) International Patent Classification:

C12N 15/12 (2006.01) *C07K 7/06* (2006.01)
A61K 9/50 (2006.01) *C07K 14/47* (2006.01)
A61K 9/51 (2006.01) *C07K 14/725* (2006.01)
A61K 35/12 (2015.01) *C07K 16/28* (2006.01)
A61K 38/08 (2019.01) *C07K 19/00* (2006.01)
A61K 39/00 (2006.01) *C12N 5/10* (2006.01)
A61P 35/00 (2006.01) *C12N 15/62* (2006.01)
A61P 37/04 (2006.01) *C12N 15/88* (2006.01)

(21) International Application Number:

PCT/CA2023/051050

(22) International Filing Date:

04 August 2023 (04.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/370,697 08 August 2022 (08.08.2022) US

(71) Applicant: **UNIVERSITÉ DE MONTRÉAL** [CA/CA];
2900 boul. Édouard-Montpetit, Montréal, Québec H3T 1J4
(CA).

(72) Inventors: **PERREAULT, Claude**; 70 avenue Claude-
Champagne, Montréal, Québec H2V 2X1 (CA).

THIBAUT, Pierre; 8560 rue Joseph-Quintal, Montreal,
Québec H2M 2M8 (CA). **KINA, Eralda**; 6603 26e Avenue,
Montréal, Québec H1T 3K8 (CA).

(74) Agent: **LAVERY, DE BILLY, LLP**; 1, Place Ville Marie,
Bureau 4000, Montréal, Québec H3B 4M4 (CA).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: NOVEL ANTIGENS FOR CANCER AND USES THEREOF




FIG. 7D

(57) Abstract: Breast cancer is now the most prevalent cancer worldwide, and despite therapeutical advances in the last decades, metastatic breast cancer remains an incurable disease. Novel tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs) expressed by breast tumor cells are described herein. Synthetic long peptides, nucleic acids, compositions, cells, TCRs, antibodies and vaccines derived from these TSAs and TAAs are described. The use of the TSAs/TAAs, nucleic acids, compositions, antibodies, cells and vaccines for the prevention or treatment of breast cancer, including triple-negative breast cancer (TNBC), is also described.

[Continued on next page]

WO 2024/031181 A1

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*